These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27100772)

  • 21. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of IgA response among women with incident HPV 16 infection.
    Onda T; Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
    Virology; 2003 Jul; 312(1):213-21. PubMed ID: 12890634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers.
    Marais DJ; Carrara H; Ramjee G; Kay P; Williamson AL
    J Med Virol; 2009 Feb; 81(2):203-10. PubMed ID: 19107974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
    De Carvalho N; Teixeira J; Roteli-Martins CM; Naud P; De Borba P; Zahaf T; Sanchez N; Schuind A
    Vaccine; 2010 Aug; 28(38):6247-55. PubMed ID: 20643092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
    J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
    Zhu FC; Li CG; Pan HX; Zhang YJ; Bi D; Tang HW; Datta S
    Chin J Cancer; 2011 Aug; 30(8):559-64. PubMed ID: 21801604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection.
    Gradissimo A; Shankar V; Wiek F; St Peter L; Studentsov Y; Nucci-Sack A; Diaz A; Pickering S; Schlecht NF; Burk RD
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.
    Ngan HY; Cheung AN; Tam KF; Chan KK; Tang HW; Bi D; Descamps D; Bock HL
    Hong Kong Med J; 2010 Jun; 16(3):171-9. PubMed ID: 20519752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
    Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Schulze K; Poncelet SM; Catteau G; Thomas F; Descamps D
    Hum Vaccin; 2011 Sep; 7(9):958-65. PubMed ID: 21892005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
    Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
    J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
    Nardelli-Haefliger D; Lurati F; Wirthner D; Spertini F; Schiller JT; Lowy DR; Ponci F; De Grandi P
    Vaccine; 2005 May; 23(28):3634-41. PubMed ID: 15882523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.
    Moscicki AB; Wheeler CM; Romanowski B; Hedrick J; Gall S; Ferris D; Poncelet S; Zahaf T; Moris P; Geeraerts B; Descamps D; Schuind A
    Vaccine; 2012 Dec; 31(1):234-41. PubMed ID: 23063422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
    Nardelli-Haefliger D; Wirthner D; Schiller JT; Lowy DR; Hildesheim A; Ponci F; De Grandi P
    J Natl Cancer Inst; 2003 Aug; 95(15):1128-37. PubMed ID: 12902442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.
    Schwarz T; Spaczynski M; Kaufmann A; Wysocki J; Gałaj A; Schulze K; Suryakiran P; Thomas F; Descamps D
    BJOG; 2015 Jan; 122(1):107-18. PubMed ID: 25208608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
    Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
    J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.